Strategic consulting for medical devices – your path through MDR, IVDR and international markets
Today, the development and approval of medical devices is more complex than ever. Different regulations in the EU, UK, USA and other international markets require a well thought-out strategy that goes far beyond individual approval steps. At BAYOOCARE, we work with you to develop an integrated overall regulatory strategy that links your product, your target markets and your business model right from the start – from the initial concept to the post-market phase.
Why a regulatory strategy is crucial
Many medical device manufacturers start with an innovative concept but underestimate the regulatory requirements for market access. The result: delays in approval, unexpected additional costs or, in the worst case, rejection by notified bodies and authorities. A well thought-out regulatory strategy prevents such risks by setting the right course in the early development phase.
The EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) have significantly tightened the requirements for technical documentation, clinical evaluation and post-market surveillance. At the same time, the USA with its FDA approval channels (510(k), De Novo, PMA) requires different proof and evidence standards. If you want to operate in several markets, you need to combine these different requirements into a consistent strategy from the outset.
We support you in correctly classifying risks, identifying the appropriate approval path and developing a roadmap that synchronizes regulatory milestones with your product development and business goals. In this way, you avoid costly detours and maintain an overview of all relevant requirements along the entire product life cycle.
Product and market strategy: the basis for all regulatory decisions
Every successful regulatory strategy starts with a precise definition of your medical device. Together with you, we clarify the intended purpose, the target groups, the application environment and the clinical benefit. These fundamentals form the basis for the correct classification according to MDR/IVDR (Class I to III or A to D) and determine which conformity assessment procedure and which notified body are required.
At the same time, we analyze the competitive environment and the current standard of care in your target markets. This assessment helps us to sharpen your positioning and derive realistic evidence requirements. For international markets, we also examine country-specific features – such as regulatory differences in the UK following Brexit, FDA requirements for the US market or approval processes in Asia and Latin America.
Regulatory roadmap: Your roadmap from classification to market launch
A robust roadmap is at the heart of every regulatory strategy. We develop a tailor-made step-by-step plan for you that systematically guides you through all the necessary milestones: from product classification to the selection of the notified body and the creation of technical documentation through to CE marking and post-market activities.
We clearly define which requirements apply to your conformity assessment procedure – whether full testing, type examination or other procedures in accordance with Annex IX to XI of the MDR. We clarify which documents must be available and when: Risk analysis according to ISO 14971, clinical evaluation according to MEDDEV 2.7/1 Rev. 4, instructions for use, performance evaluation for IVDs and all other components of the technical documentation.
We coordinate your roadmap closely with your internal development, study and market launch plans. In this way, we ensure that regulatory and economic objectives go hand in hand and that there are no delays due to missing evidence or incomplete documentation.
Evidence and study strategy: convincing clinical data
The clinical evaluation according to MDR and the performance evaluation according to IVDR are among the most demanding requirements of the new regulations. We develop an evidence strategy for you that is tailored to your product, your risk class and your target markets. We use all available data sources: Literature data, clinical studies, real-world evidence and data from equivalent or similar products.
If clinical studies are required, we support you from planning to evaluation. We support you in the development of study protocols, the selection of relevant endpoints, the design of the study and communication with ethics committees. We then integrate the study results into your clinical evaluation and use them for the benefit-risk assessment – a key element of MDR/IVDR compliance.
For the US market, we advise you on the different evidence requirements of the FDA routes: while a comparison with predicate devices is often sufficient for 510(k) approvals, de novo and PMA procedures require more comprehensive clinical data. We help you to find the right balance between effort and regulatory certainty.
QMS and risk management integration: strategy meets process architecture
A regulatory strategy can only be fully effective if it is consistently integrated into your quality management system in accordance with ISO 13485. We support you in setting up or optimizing your process architecture so that development, document control, clinical data and post-market surveillance are seamlessly integrated.
Systematic risk management over the entire product life cycle is particularly important. Based on ISO 14971 and the specific requirements of the MDR/IVDR, we work with you to develop a risk management process that ranges from the initial risk analysis and risk controls to the final risk-benefit assessment. We document the results in a consistent risk management file that also convinces notified bodies and authorities.
When audits are due – whether by your notified body, authorities or as part of internal audits – we prepare you specifically. We use mock audits and gap analyses to identify weaknesses at an early stage and close them before the official audit begins.
Combination products: When medicinal product meets medical device
Combination products consisting of a drug and a device pose particular regulatory challenges. The central question is: Is your product “drug-led” or “device-led”? This classification determines which main route applies – drug law with EMA procedure or medical device law with CE marking.
Together with you, we evaluate the regulatory classification and develop a strategy that integrates quality, safety, efficacy and labeling requirements from both worlds. We support you in communicating with authorities (EMA, FDA, notified bodies) and in preparing the necessary dossiers – for example in the European centralized procedure or for FDA combination product applications.
MDR/IVDR impact analyses: making existing products future-proof
Many manufacturers have to adapt existing medical devices to the stricter MDR/IVDR requirements. We carry out structured impact analyses for you to assess how the new regulations will affect your technical documentation, labeling, clinical evaluation and post-market surveillance concept.
Based on this analysis, we develop an action plan that prioritizes which adjustments are required and in which order they should be implemented. This gives you clarity about the effort involved and allows you to plan resources in a targeted manner.
Every medical device is unique – which is why we tailor our advice to your specific situation. Whether you are a start-up developing your first product, an established medtech company looking to tap into new markets or a pharmaceutical company wanting to bring a combination product to market: We tailor the depth and pace of our advice to your level of maturity and resources.
We provide you with a central point of contact who accompanies your entire MedTech journey – from the initial idea through development and approval to ongoing lifecycle management. We translate the regulatory strategy into concrete projects, processes and documents that you can implement directly. We always keep the big picture in mind: Your strategy must not only be regulatory compliant, but also economically viable and operationally feasible.
A well thought-out regulatory strategy is the key to the successful market launch of your medical device. We have answered the most frequently asked questions about classification, approval routes and strategic planning for you. Your question is not listed? Please feel free to contact us.
